PharmaShots Weekly Snapshots ( October 30– November 03, 2023)
This week PharmaShots’ news was all about the updates on clinical trials, regulatory, pharma, M&A, MedTech, and DigiHealth. Check out our full report below:
The US FDA Approved Merck’s Keytruda with Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer
Read More:- Merck
Coherus and Junshi Bioscience's Loqtorzi (toripalimab-tpzi) Received the US FDA’s Approval to Treat Nasopharyngeal Carcinoma (NPC)
Read More:- Coherus and Junshi Bioscience
The US FDA Grants Santhera’s Agamree (vamorolone) Approval for the Treatment of Duchenne Muscular Dystrophy (DMD)
Idorsia Pharmaceuticals Reports the NDA Submission of Daridorexant to the PMDA for the Treatment of Insomnia
Read More:- Idorsia Pharmaceuticals
BMS Receives EMA’s Validation of Opdivo (nivolumab) + Cisplatin-Based CT for 1L Treatment of Unresectable or Metastatic Urothelial Carcinoma
Read More:- BMS
Novartis Received The US FDA's Approval for Cosentyx to Treat Hidradenitis Suppurativa
Read More:- Novartis
The US FDA Approved Amgen's Wezlana (Biosimilar, ustekinumab) for the Treatment of Multiple Inflammatory Diseases
Read More:- Amgen
Abbott's Alinity M High Risk (HR) HPV assay for the Detection of HPV Infections has been approved by the US FDA
Read More:- Abbott
The US FDA has accepted to review the resubmitted NDA of Supernus' SPN-830 for the Treatment of Off Episodes in Parkinson’s Disease
Read More:- Supernus
GSK Reports Positive Results of P-III Study (RUBY) for Jemperli + CT in Primary Advanced or Recurrent Endometrial Cancer Patients
Read More:- GSK
Novartis’ Reports Results of Atrsentan in P-III Study for the Treatment of IgA Nephropathy
Read More:- Novartis
Otsuka Pharmaceutical Reports Results for Centanafadine in Two P-III Trials for the Treatment of ADHD
Read More:- Otsuka Pharmaceutical
Teva Pharmaceutical Reports P-III Results of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia
Read More:- Teva Pharmaceutical
T3D Therapeutics has announced promising outcomes from the P-II study (PIONEER) of T3D-959 in the treatment of Alzheimer's Disease
Read More:- T3D Therapeutics
Innate Pharma Presents P-II Study (TELLOMAK) Results of Lacutamab for the Treatment of Sézary Syndrome
Read More:- Innate Pharma
Roche Reports Positive Efficacy Results from the P-III Study (EMBARK) of Elevidys for Duchenne Muscular Dystrophy (DMD)
Read More:- Roche
Merck Reports Secondary Endpoint Results of Keytruda in P-III Trial for the Treatment of Renal Cell Carcinoma (RCC)
Read More:- Merck
Adaptimmune Reports Positive Data from the P-II Trial Assessing Lete-cel for the Treatment of Synovial Sarcoma And Myxoid/Round Cell Liposarcoma (MRCLS)
Read More:- Adaptimmune
UCB Publishes the Results for Nayzilam in P-III Trial for the Treatment of Epilepsy in ‘Epilepsy & Behavior’
Read More:- UCB
Henlius Brings Hansizhuang (serplulimab injection) to Europe and India Through an Exclusive Licensing Agreement with Accord Healthcare
Read More:- Henlius & Accord Healthcare
Sosei Heptares Receives a Milestone Payment of $3.75M as a Part of its Multi-Target Agreement with Genentech
Read More:- Sosei Heptares & Genentech
Merck KGaA and Hengrui Pharma Entered into a Licensing Agreement for the Development of HRS-1167 and SHR-A1904 to Treat Cancer
Read More:- Merck KGaA and Hengrui Pharma
Zydus and Guardant Health will Co-Promote the Guardant360 portfolio which includes Guardant360 and Guardant360 TissueNext tests for advanced solid cancers in India and Nepal
Read More:- Zydus and Guardant Health
AstraZeneca Signs a Collaboration Agreement with Cellectis to Develop Novel Cell and Gene Therapies for Oncology and Immunology Indications
Read More:- AstraZeneca & Cellectis
Abcellera and Prelude Therapeutics Entered into a Partnership to Develop ADCs Therapies for the Treatment of Cancer
Read More:- Abcellera and Prelude Therapeutics
Aldeyra Therapeutics Signs an Agreement with AbbVie for Reproxalap to Treat Dry Eye Disease
Read More:- Aldeyra Therapeutics & AbbVie
GSK Enters into an Agreement with Janssen and Arrowhead for JNJ-3989 to Treat Chronic Hepatitis B
Read More:- GSK, Janssen and Arrowhead
Abbott Reports Trial Data for Esprit BTK Drug-Eluting Resorbable Scaffold to Treat Chronic Limb-Threatening Ischemia (CLTI)
Read More:- Abbott
Shorla Oncology Acquires Jylamvo form Therakind as a Therapy Targeting Oncology and Autoimmune Indications
Read More:- Shorla Oncology & Jylamvo
The collaboration marks the expansion between R1 RCM and Microsoft to develop and integrate Generative AI and Revenue Cycle Management Platform
Read More:- R1 RCM and Microsoft
Related Post: PharmaShots Weekly Snapshots (October 23–27, 2023)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.